PNC Managed Account Solutions’s 10x Genomics TXG Stock Holding History

PNC Managed Account Solutions’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	$141K	Buy	+718	New	+$130K	0.03%	256

Other funds holding TXG

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

1WCM

12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return

MCAV

Meritech Capital Associates V Palo Alto, California $141M AUM 15.44% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

PNC Managed Account Solutions's TXG Position: Q2 2021 in Review

PNC Managed Account Solutions opened a new position in 10x Genomics (TXG) in Q2 2021: 718 shares worth $141K. The stake represents 0.03% of the portfolio and ranks #256 among its holdings.

340 funds tracked by Wall St. Rank hold TXG as of Q2 2021.

PNC Managed Account Solutions held 718 shares of 10x Genomics worth $141K as of Q2 2021.
10x Genomics was a new PNC Managed Account Solutions position in Q2 2021.
10x Genomics made up 0.03% of PNC Managed Account Solutions's portfolio in Q2 2021, its #256 holding.
340 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2021.

Based on PNC Managed Account Solutions's 13F filing for Q2 2021, filed 6 Aug 2021.